Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

Rare cause of spontaneous haemothorax: mediastinal and distant lymph node metastases from uveal melanoma.

Reznitsky F, Klausen S, Donia M, Scheie D.

BMJ Case Rep. 2019 Nov 21;12(11). pii: e231534. doi: 10.1136/bcr-2019-231534.

PMID:
31753826
2.

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.

Bol KF, Ellebaek E, Hoejberg L, Bagger MM, Larsen MS, Klausen TW, Køhler UH, Schmidt H, Bastholt L, Kiilgaard JF, Donia M, Svane IM.

Cancers (Basel). 2019 Oct 3;11(10). pii: E1489. doi: 10.3390/cancers11101489.

3.

A metagenomic strategy for harnessing the chemical repertoire of the human microbiome.

Sugimoto Y, Camacho FR, Wang S, Chankhamjon P, Odabas A, Biswas A, Jeffrey PD, Donia MS.

Science. 2019 Oct 3. pii: eaax9176. doi: 10.1126/science.aax9176. [Epub ahead of print]

PMID:
31582523
4.

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.

Molnár E, Garay T, Donia M, Baranyi M, Rittler D, Berger W, Tímár J, Grusch M, Hegedűs B.

Int J Mol Sci. 2019 Sep 11;20(18). pii: E4484. doi: 10.3390/ijms20184484.

5.

Role of Fused Three-Dimensional Time-of-Flight Magnetic Resonance Angiography and 3-Dimensional T2-Weighted Imaging Sequences in Neurovascular Compression.

Gamaleldin OA, Donia MM, Elsebaie NA, Abdelkhalek Abdelrazek A, Rayan T, Khalifa MH.

World Neurosurg. 2019 Sep 4. pii: S1878-8750(19)32346-0. doi: 10.1016/j.wneu.2019.08.190. [Epub ahead of print]

PMID:
31493603
6.

The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous.

Ellebaek E, Bastholt L, Schmidt H, Svane IM, Donia M.

Int J Cancer. 2019 Dec 1;145(11):3173-3174. doi: 10.1002/ijc.32631. Epub 2019 Sep 3. No abstract available.

PMID:
31423583
7.

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.

Friedrich M, Jasinski-Bergner S, Lazaridou MF, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, Donia M, Mandelboim O, Seliger B.

Cancer Immunol Immunother. 2019 Oct;68(10):1689-1700. doi: 10.1007/s00262-019-02373-1. Epub 2019 Aug 3. Review.

PMID:
31375885
8.

Real-world evidence to guide healthcare policies in oncology.

Donia M, Hansen SW, Svane IM.

Oncotarget. 2019 Jul 16;10(44):4513-4515. doi: 10.18632/oncotarget.27077. eCollection 2019 Jul 16.

9.

Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells.

Saini SK, Tamhane T, Anjanappa R, Saikia A, Ramskov S, Donia M, Svane IM, Jakobsen SN, Garcia-Alai M, Zacharias M, Meijers R, Springer S, Hadrup SR.

Sci Immunol. 2019 Jul 19;4(37). pii: eaau9039. doi: 10.1126/sciimmunol.aau9039.

PMID:
31324690
10.

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Nov;58(11):1603-1611. doi: 10.1080/0284186X.2019.1633015. Epub 2019 Jul 4.

PMID:
31271119
11.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
12.

A microbial factory for defensive kahalalides in a tripartite marine symbiosis.

Zan J, Li Z, Tianero MD, Davis J, Hill RT, Donia MS.

Science. 2019 Jun 14;364(6445). pii: eaaw6732. doi: 10.1126/science.aaw6732.

PMID:
31196985
13.

De novo Blood Biomarkers in Autism: Autoantibodies against Neuronal and Glial Proteins.

Abou-Donia MB, Suliman HB, Siniscalco D, Antonucci N, ElKafrawy P.

Behav Sci (Basel). 2019 Apr 29;9(5). pii: E47. doi: 10.3390/bs9050047.

14.

Potential of marine natural products against drug-resistant bacterial infections.

Liu M, El-Hossary EM, Oelschlaeger TA, Donia MS, Quinn RJ, Abdelmohsen UR.

Lancet Infect Dis. 2019 Jul;19(7):e237-e245. doi: 10.1016/S1473-3099(18)30711-4. Epub 2019 Apr 25. Review.

PMID:
31031171
15.

Localized production of defence chemicals by intracellular symbionts of Haliclona sponges.

Tianero MD, Balaich JN, Donia MS.

Nat Microbiol. 2019 Jul;4(7):1149-1159. doi: 10.1038/s41564-019-0415-8. Epub 2019 Apr 1.

PMID:
30936484
16.

Peptide Super-Agonist Enhances T-Cell Responses to Melanoma.

Galloway SAE, Dolton G, Attaf M, Wall A, Fuller A, Rius C, Bianchi V, Theaker S, Lloyd A, Caillaud ME, Svane IM, Donia M, Cole DK, Szomolay B, Rizkallah P, Sewell AK.

Front Immunol. 2019 Mar 13;10:319. doi: 10.3389/fimmu.2019.00319. eCollection 2019.

17.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Apr;120(8):870. doi: 10.1038/s41416-019-0425-6.

18.

Collagen density regulates the activity of tumor-infiltrating T cells.

Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersbæk MS, Simões AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Grøntved L, Madsen DH.

J Immunother Cancer. 2019 Mar 12;7(1):68. doi: 10.1186/s40425-019-0556-6.

19.

Influence of Pickling Process on Allium cepa and Citrus limon Metabolome as Determined via Mass Spectrometry-Based Metabolomics.

Farag MA, Tawfike AF, Donia MS, Ehrlich A, Wessjohann LA.

Molecules. 2019 Mar 7;24(5). pii: E928. doi: 10.3390/molecules24050928.

20.

Detection of Natural Products and Their Producers in Ocean Sediments.

Tuttle RN, Demko AM, Patin NV, Kapono CA, Donia MS, Dorrestein P, Jensen PR.

Appl Environ Microbiol. 2019 Apr 4;85(8). pii: e02830-18. doi: 10.1128/AEM.02830-18. Print 2019 Apr 15.

21.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Feb;120(4):424-434. doi: 10.1038/s41416-019-0384-y. Epub 2019 Feb 5. Erratum in: Br J Cancer. 2019 Apr;120(8):870.

PMID:
30718808
22.

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.

Forsberg EMV, Lindberg MF, Jespersen H, Alsén S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA.

Cancer Res. 2019 Mar 1;79(5):899-904. doi: 10.1158/0008-5472.CAN-18-3158. Epub 2019 Jan 8.

PMID:
30622115
23.

The real-world impact of modern treatments on the survival of patients with metastatic melanoma.

Donia M, Ellebaek E, Øllegaard TH, Duval L, Aaby JB, Hoejberg L, Køhler UH, Schmidt H, Bastholt L, Svane IM.

Eur J Cancer. 2019 Feb;108:25-32. doi: 10.1016/j.ejca.2018.12.002. Epub 2018 Dec 31.

PMID:
30605822
24.

Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs.

Draghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, Donia M.

Int J Cancer. 2019 Sep 1;145(5):1408-1413. doi: 10.1002/ijc.32080. Epub 2019 Jan 7.

PMID:
30575963
25.

Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM.

Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. eCollection 2018.

26.

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Bjoern J, Lyngaa R, Andersen R, Hölmich LR, Hadrup SR, Donia M, Svane IM.

Oncotarget. 2018 Nov 9;9(88):35870. doi: 10.18632/oncotarget.26359. eCollection 2018 Nov 9.

27.

Principles of adoptive T cell therapy in cancer.

Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM.

Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. Review.

PMID:
30187086
28.

Acquired resistance to cancer immunotherapy.

Draghi A, Chamberlain CA, Furness A, Donia M.

Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2. Review.

PMID:
29968044
29.

Aortic root dynamism, geometry, and function after the remodeling operation: Clinical relevance.

Yacoub MH, Aguib H, Gamrah MA, Shehata N, Nagy M, Donia M, Aguib Y, Saad H, Romeih S, Torii R, Afifi A, Lee SL.

J Thorac Cardiovasc Surg. 2018 Sep;156(3):951-962.e2. doi: 10.1016/j.jtcvs.2018.03.157. Epub 2018 Apr 13.

PMID:
29884493
30.

[Cancer immunotherapy].

Kjeldsen JW, Donia M, Svane IM.

Ugeskr Laeger. 2018 May 21;180(21). pii: V09170691. Review. Danish.

PMID:
29804567
31.

Tubulin and Tau: Possible targets for diagnosis of Parkinson's and Alzheimer's diseases.

Salama M, Shalash A, Magdy A, Makar M, Roushdy T, Elbalkimy M, Elrassas H, Elkafrawy P, Mohamed W, Abou Donia MB.

PLoS One. 2018 May 9;13(5):e0196436. doi: 10.1371/journal.pone.0196436. eCollection 2018.

32.

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.

Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH.

Oncoimmunology. 2018 Feb 1;7(5):e1424674. doi: 10.1080/2162402X.2018.1424674. eCollection 2018.

33.

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.

Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M.

Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139.

PMID:
29688262
34.

Cancer immunotherapy in patients with brain metastases.

Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M.

Cancer Immunol Immunother. 2018 May;67(5):703-711. doi: 10.1007/s00262-018-2146-8. Epub 2018 Mar 8. Review.

PMID:
29520474
35.

Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK.

J Immunol. 2018 Apr 1;200(7):2263-2279. doi: 10.4049/jimmunol.1700242. Epub 2018 Feb 26.

36.

Frequent adaptive immune responses against arginase-1.

Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018.

37.

Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson's Disease Relative to Alzheimer's Disease and Controls.

Shalash A, Salama M, Makar M, Roushdy T, Elrassas HH, Mohamed W, El-Balkimy M, Abou Donia M.

Front Neurol. 2017 Dec 22;8:720. doi: 10.3389/fneur.2017.00720. eCollection 2017.

38.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH.

Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018.

39.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM.

Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4.

40.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T, Kvist A, Ringnér M, Svane IM, Jönsson G.

Nat Commun. 2017 Nov 23;8(1):1738. doi: 10.1038/s41467-017-01460-0.

41.

Amyotrophic lateral sclerosis-A case report and mechanistic review of the association with toluene and other volatile organic compounds.

Ratner MH, Jabre JF, Ewing WM, Abou-Donia M, Oliver LC.

Am J Ind Med. 2018 Mar;61(3):251-260. doi: 10.1002/ajim.22791. Epub 2017 Nov 10. Review.

PMID:
29125194
42.

Neural autoantibodies in patients with neurological symptoms and histories of chemical/mold exposures.

Abou-Donia MB, Lieberman A, Curtis L.

Toxicol Ind Health. 2018 Jan;34(1):44-53. doi: 10.1177/0748233717733852. Epub 2017 Oct 25.

PMID:
29069985
43.

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA.

Nat Commun. 2017 Sep 27;8(1):707. doi: 10.1038/s41467-017-00786-z.

44.

A Panel of Autoantibodies Against Neural Proteins as Peripheral Biomarker for Pesticide-Induced Neurotoxicity.

El Rahman HAA, Salama M, Gad El-Hak SA, El-Harouny MA, ElKafrawy P, Abou-Donia MB.

Neurotox Res. 2018 Feb;33(2):316-336. doi: 10.1007/s12640-017-9793-y. Epub 2017 Sep 5.

PMID:
28875469
45.

Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells.

Cervantes-Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J, Cortez VS, Caparon MG, Donia MS, Gilfillan S, Cella M, Gordon JI, Hsieh CS, Colonna M.

Science. 2017 Aug 25;357(6353):806-810. doi: 10.1126/science.aah5825. Epub 2017 Aug 3.

46.

PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.

Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S, Dolton G, Lyngaa R, Hadrup SR, Sewell AK, Svane IM.

Clin Cancer Res. 2017 Oct 1;23(19):5779-5788. doi: 10.1158/1078-0432.CCR-16-1692. Epub 2017 Jul 5.

47.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

48.

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Bjoern J, Lyngaa R, Andersen R, Hölmich LR, Hadrup SR, Donia M, Svane IM.

Oncotarget. 2017 Apr 18;8(16):27062-27074. doi: 10.18632/oncotarget.16003. Erratum in: Oncotarget. 2018 Nov 9;9(88):35870. Rosenkrantz, Lisbet Hölmich [corrected to Hölmich, Lisbet Rosenkrantz].

49.

Genomic Methods and Microbiological Technologies for Profiling Novel and Extreme Environments for the Extreme Microbiome Project (XMP).

Tighe S, Afshinnekoo E, Rock TM, McGrath K, Alexander N, McIntyre A, Ahsanuddin S, Bezdan D, Green SJ, Joye S, Stewart Johnson S, Baldwin DA, Bivens N, Ajami N, Carmical JR, Herriott IC, Colwell R, Donia M, Foox J, Greenfield N, Hunter T, Hoffman J, Hyman J, Jorgensen E, Krawczyk D, Lee J, Levy S, Garcia-Reyero N, Settles M, Thomas K, Gómez F, Schriml L, Kyrpides N, Zaikova E, Penterman J, Mason CE.

J Biomol Tech. 2017 Apr;28(1):31-39. doi: 10.7171/jbt.17-2801-004. Epub 2017 Mar 10. Erratum in: J Biomol Tech. 2017 Jul;28(2):93.

50.

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.

Donia M, Kimper-Karl ML, Høyer KL, Bastholt L, Schmidt H, Svane IM.

Eur J Cancer. 2017 Mar;74:89-95. doi: 10.1016/j.ejca.2016.12.017. Epub 2017 Feb 12.

PMID:
28335891

Supplemental Content

Support Center